INVO BioScience,INC Stock Price, News & Analysis

INVO Bioscience, Inc. (Nasdaq: INVO) has announced the launch of its intravaginal culture (IVC) treatment using the INVOcell medical device at Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz in Kuala Lumpur, Malaysia. This follows the successful completion of the first IVC case, which received recognition at the Obstetrical and Gynecological Society of Malaysia conference. The center expects to provide IVC to a significant number of patients by the end of 2022, supported by Malaysian government officials.

INVO Bioscience, Inc. (Nasdaq: INVO) reported its second quarter financial results for 2022, showing revenue of approximately $146,000, down 30% from $208,000 in Q2 2021. The decrease was attributed to lost Ferring licensing revenue. However, patient inquiries rose 20% quarter-over-quarter as the company plans to open new INVO Centers and has signed a $14 million distribution deal for China. Management anticipates significant revenue growth in Q3 2022 based on increased clinic activity.

INVO Bioscience (NASDAQ: INVO) will release its second quarter 2022 financial results on August 15, 2022, after market close. A conference call to discuss these results will take place at 4:30 pm ET on the same day. The company is committed to enhancing fertility treatment accessibility with its INVOcell® device and aims to increase its market presence through dedicated INVO Centers. These efforts reflect INVO's focus on patient-centered solutions in assisted reproductive technology.

INVO Bioscience, Inc. (Nasdaq: INVO) announced a Facebook Live event titled "Get to Know INVOcell" hosted by Dr. Sue Ellen Carpenter from Bloom Fertility in Atlanta on July 7, 2022. The event aims to educate participants about INVOcell, a medical device enabling fertilization and embryo development within the woman's body, offering a more affordable and personal alternative to traditional fertility treatments. Interested individuals can join the live session and schedule a complimentary consultation.

INVO Bioscience, Inc. (Nasdaq: INVO) has signed an exclusive distribution agreement with Onesky Holdings Limited for its INVOcell medical device in Mainland China. Onesky will register the product and must purchase approximately $14 million worth of INVOcell over five years post-approval. This agreement aims to address the significant infertility issue in China, affecting nearly 50 million people, which presents a lucrative market opportunity for INVO. The partnership is expected to enhance product adoption through Onesky's established network of reproductive specialists.

INVO Bioscience, a fertility-focused company, reported Q1 2022 revenue of approximately $0.2 million, a 76% decline from $0.7 million in Q1 2021, due to a one-time bulk order in the prior year. Gross margins decreased to 60% from 91% year-over-year. Despite the revenue dip, patient inquiries increased by 40% across INVO Centers, signaling potential growth. The company plans to expand with new centers and signed an exclusive agreement with Onesky for distribution in China. Cash as of March 31, 2022, stood at $3.8 million.

INVO Bioscience (NASDAQ: INVO) will release its first quarter 2022 financial results after market close on May 16, 2022. The company, focused on expanding access to fertility treatments globally, will host a conference call at 4:30 pm ET on the same day to discuss these results. Its flagship product, INVOcell®, is a novel medical device that facilitates fertilization and early embryo development in vivo, providing a cost-effective alternative to traditional in vitro fertilization (IVF). This marks an important milestone in INVO's mission to enhance patient-centered fertility care.